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 1	
Abstract 2	
The Golgi Apparatus (GA) is involved in a whole spectrum of activities, from lipid 3	
biosynthesis and membrane secretion to the post-translational processing and trafficking of 4	
most proteins, to the control of mitosis, cell polarity, migration and morphogenesis, to diverse 5	
processes such as apoptosis, autophagy and the stress response. In keeping with its versatility, 6	
mutations in GA proteins lead to a number of different disorders, including syndromes with 7	
multi-system involvement. Intriguingly, however, over 40% of the GA-related genes known to 8	
be associated with disease affect the central or peripheral nervous system, highlighting the 9	
critical importance of the GA to neural function. We have previously proposed the term 10	
"Golgipathies" in relation to a group of disorders in which mutations in GA proteins or their 11	
molecular partners lead to consequences in terms of brain development, in particular postnatal-12	
onset microcephaly (POM), white matter defects and intellectual disability (ID). Here, taking 13	
into account the broader role of the GA in the nervous system, we refine and enlarge this 14	
emerging concept to include other disorders whose symptoms may be indicative of altered 15	
neurodevelopmental processes, from neurogenesis to neuronal migration, to the secretory 16	
function critical for the maturation of postmitotic neurons and myelination. 17	
  18	
Rasika et al, Golgipathies and Neurodevelopment 
	 3	
 1	
Introduction 2	
 One hundred and twenty years ago, in 1898, Camillo Golgi first published his 3	
observations of an "internal reticular complex" that surrounded the nucleus of Purkinje cells in 4	
the barn owl cerebellum, using his now eponymous silver reduction method [1]. Despite 5	
Golgi's demonstration of his reticular complex is a variety of mammalian cell types in addition 6	
to neurons, the very existence of this complex, which we now call the Golgi complex or Golgi 7	
apparatus (GA), as an independent and consistent intracellular entity was in doubt for much of 8	
the first half of its history, in large part because of its variable morphology and technological 9	
and methodological limitations. Also in doubt was what specific role, if any, this strange 10	
structure could possibly play. We have known for a few decades now that the GA not only 11	
exists but is ubiquitous in all eukaryotic cells, from the yeast upward. However, our views on 12	
what it does and how it does it continue to evolve.  13	
 The best known and most widely accepted roles of the GA are of course in the 14	
biosynthesis of some lipids such as glycolipids and sphingomyelin, and in the processing, 15	
sorting, packing, routing and recycling of secretory cargo downstream of the endoplasmic 16	
reticulum (ER), roles that are important for cellular and organ function throughout the lifespan. 17	
However, the GA plays a number of other roles, many of which are of particular importance 18	
during development – it participates in cell division, migration, morphogenesis and growth (all 19	
of which involve diverse aspects including intracellular organization, polarity and 20	
compartmentalization), as well as apoptosis, autophagy and the stress response. In keeping with 21	
these multiple roles, many "GA proteins" are also present in other intracellular compartments 22	
and are involved in more than one function, including acting as signaling molecules, rather than 23	
acting at a purely structural/mechanical or enzymatic level.  24	
  25	
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 1	
 The ubiquitous nature of the GA means that any pathogenic mutation perturbing the 2	
function of a GA protein could and mostly does result in clinical repercussions across multiple 3	
tissues and systems. Strikingly, of the mutated GA-associated genes identified in various 4	
monogenic disorders so far, over 40% affect the normal development or functioning of the 5	
central or peripheral nervous system, a far greater proportion than for any other tissue type [2], 6	
highlighting its crucial roles in different types of neural cells. Indeed, the magnitude of this 7	
impact on the nervous system structure and physiology and on neurodevelopment in particular 8	
should not be surprising, when one considers the intensive use that neurons and glia 9	
presumably make of the GA – in the intricately coordinated processes involved in progenitor 10	
cell organization, orientation and mitosis; the subsequent highly directional migration of young 11	
neurons to their target regions; the exponential increase in surface area and thus of the 12	
biosynthesis of both membrane lipids and proteins required by diverse processes such as 13	
dendritic arborization in neurons and myelin sheath production in oligodendrocytes; the heavy 14	
demands of synaptogenesis and synaptic and neurosecretory activity, etc. The existence of 15	
Golgi outposts in dendrites is a prime example of the adaptation of the GA to the highly 16	
compartmentalized nature of the nervous system and its specific trafficking needs (reviewed in 17	
[3,4]). 18	
 Intriguingly, during the course of our identification of the causal gene and molecular 19	
mechanisms underlying Dyggve-Melchior-Clausen (DMC, MIM #223800) syndrome, a 20	
disorder in which skeletal defects are associated with a characteristic neurological profile 21	
combining postnatal-onset microcephaly (POM), white matter deficits and intellectual 22	
disability (ID) [5], we noted the presence of the same combination of symptoms in several 23	
other monogenic disorders, each of which was linked to a defect in a gene involved in the GA 24	
trafficking machinery. This common profile indicated a similar pathophysiology – defective 25	
Rasika et al, Golgipathies and Neurodevelopment 
	 5	
neuronal or oligodendrocytic maturation at the post-mitotic stage, thus leading to symptoms 1	
later during neurodevelopment than in the primary or congenital microcephalies, which result 2	
principally from proliferation deficits. Additionally, several of these newly or previously 3	
identified disorders appeared to involve a mutation in a GA-associated member of the small 4	
RAB GTPase family, which are involved in a plethora of trafficking functions in the cell, or in 5	
molecules that interact with the RABs, including their direct effectors and modulators such as 6	
the guanine nucleotide exchange factors – GEFs – which activate them by replacing GDP by 7	
GTP and allowing them to bind specific effectors, or the GTPase activating proteins – GAPs, 8	
which dissociate the active complex. These observations prompted us to propose the term 9	
"Golgipathies" or "Golgipathic microcephalies" to designate this emerging class of disorders 10	
characterized by a similar phenotype (POM, white matter deficits, notably an abnormal corpus 11	
callosum, and varying degrees of cognitive impairment), and caused by mutations in RAB 12	
GTPases or their molecular partners [4]. However, an examination of the literature and recently 13	
published studies provides ample evidence that defective GA proteins and processes are linked 14	
to a wide spectrum of neurodevelopmental defects in addition to the combination that first drew 15	
our attention. Not only are there a large number of isolated reports of POM related to GA- or 16	
RAB-associated mutations, but a number of other disorders, including several characterized by 17	
congenital microcephaly, could also justifiably be classified as Golgipathies, based on the fact 18	
that the primary pathogenic mechanism in all of them is a defective GA protein, regardless of 19	
its intracellular function (GA structure or intracellular organization, trafficking machinery in 20	
the anterograde or retrograde directions, post-translational modifications, cell-cycle 21	
involvement…). In light of these new insights, we would like to refine the notion of 22	
Golgipathies, taking into account their major neurodevelopmental involvement, with a brief 23	
discussion of the relationship between these disorders and the possible GA functions affected. 24	
  25	
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 1	
Golgipathies: more microcephalies and more than microcephalies 2	
 Despite their great variety, Golgipathies with a neurodevelopmental component also 3	
show considerable overlap and a number of unifying features. Some of these putative 4	
neurodevelopmental Golgipathies are described below, grouped according to their principal 5	
clinical signs (presence or absence of microcephaly and its onset), and the probable function or 6	
position in the trafficking pathway of the affected protein, in order to stimulate discussion as to 7	
their potential classification. We have excluded cancer-related GA genes/proteins or those 8	
involved in primarily neurodegenerative processes. 9	
 10	
I. POM Golgipathies related to RAB GTPases and their molecular partners: 11	
 Perhaps due to the fact that most important and "permanent" functions of the GA is that 12	
of lipid and protein trafficking, crucial throughout the lifespan of the cell, the POMs constitute 13	
a disproportionately large group of Golgipathies affecting neurodevelopment. While many 14	
involve other organs and tissues and show remarkable differences in phenotype between one 15	
individual and the next, for the purposes of this review, we will concentrate on the neurological 16	
aspects (summarized in Table 1). 17	
Dyggve-Melchior-Clausen syndrome (DMC; MIM #223800), which first prompted our 18	
speculation about Golgipathies as a class of disorders, is an autosomal recessive skeletal 19	
dysplasia associated with POM and ID, and caused by loss-of-function mutations in the DYM 20	
gene encoding DYMECLIN, a GA protein involved in intracellular trafficking [6-8]. Brain 21	
MRI reveals a marked thinning of the corpus callosum and brain stem, supported by significant 22	
deficits in the volume and structure of myelin in Dym-/- mutant mice [5] Dym-deficient 23	
neurons display a fragmented GA and impaired ER-to-GA trafficking [5], but Dym may also 24	
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play a role in the retrograde transport of vesicles from the GA to the ER [7]. Several lines of 1	
evidence suggest that it has a tethering role during vesicle trafficking between the ER and the 2	
GA [6,7] in conjunction with the golgin GIANTIN and interactions with RAB1 or RAB6, the 3	
most abundant type of RAB [9-11]. Interestingly, Smith McCort dysplasia, a clinical variant of 4	
DMC syndrome with identical skeletal defects but normal intelligence and no microcephaly, 5	
has been found to result either from specific missense mutations in DYM that could result in 6	
some residual activity of the protein (SMC1; MIM #607326) [6,12] or from loss-of-function 7	
mutations in the RAB33B GTPase, also localized in the GA (SMC2; MIM #615222) [13,14].  8	
 Warburg-Micro syndrome (WARBM1-4; MIM #600118, #614225, #614222, #615663) 9	
is an autosomal recessive disorder [15] characterized by neurodevelopmental defects including 10	
POM with profound ID, and progressive limb spasticity associated with progressive peripheral 11	
axonal neuropathy [16], severe visual impairment and hypogonadism. Brain MRI shows 12	
bilateral frontal polymicrogyria and hypoplasia of the corpus callosum and cerebellar vermis 13	
[17,18]. Loss-of-function mutations in four distinct genes, RAB3GAP1, RAB3GAP2, RAB18 14	
and TBC1D20, have been implicated in WARBM [18-20]. RAB18 has recently been confirmed 15	
to localize in the ER and the cis-Golgi compartment	 [21], in addition to other compartments. 16	
While TBC1D20 acts as a GAP for RAB18, in addition to acting on ER-localized RAB1 [22] 17	
the RAB3GAP complex in this context acts not as a GAP but as a GEF for RAB18 [23]. In the 18	
related Martsolf syndrome (MIM #212720), only RAB3GAP2 mutations have been identified, 19	
but most patients also display severe neurodevelopmental defects including POM and white 20	
matter defects (where examined), ID, hypogonadism and ocular defects [19,24,25]. 21	
 Mutations in COL4A3BP (collagen 4A3 binding protein, also known as Goodpasture 22	
antigen binding protein, GPBP, or ceramide transporter, CERT) lead to an autosomal dominant 23	
mental retardation (MRD34; MIM #616351). The COL4A3BP protein is thought to mediate 24	
ER-to-GA transport of ceramide, an essential lipid component. One of the first patients 25	
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identified with a mutation in this gene presented with POM in addition to other neurological 1	
and skeletal defects [26]. 2	
 Autosomal recessive mental retardation 13 (MRT13; MIM #613192) is linked to loss-3	
of-function mutations in TRAPPC9. Initially considered a nonsyndromic autosomal recessive 4	
ID	[27-29], with additional cases, MRT13 is beginning to show a fairly distinctive phenotype, 5	
including moderate to severe POM, a peculiar facial appearance, obesity and hypotonia. MRI 6	
reveals a reduction in cerebral white matter with a marked thinning of the corpus callosum	[30-7	
32]. TRAPPC9 is a subunit of the Trafficking Protein Particle (TRAPP) complex that mediates 8	
the tethering of COPII-coated ER-derived vesicles to cis-Golgi membranes [33]. The TRAPP 9	
complex acts by activating RAB1, which in turn recruits specific cis-Golgi effectors such as the 10	
golgins P115 and GM130 to allow vesicle tethering [34]. The TRAPP complex and TRAPPC9 11	
in particular are also involved in the interaction between COPII-coated vesicles and the 12	
microtubule motor protein dynactin 1 (DCTN1, equivalent to the Drosophila p150Glued) [35].  13	
 Progressive childhood encephalopathy (PEBAS; MIM #617669), also linked to 14	
mutations in a TRAPP subunit, TRAPPC12, has been identified in 2 families as being linked to 15	
progressive microcephaly (including one case of POM), agenesis of the corpus callosum and 16	
other MRI abnormalities, and severe developmental delays [36]. Mutations in another TRAPP 17	
subunit, TRAPPC6B, have also been linked to a POM syndrome (NEDMEBA; MIM #617862) 18	
in several families in a recent report [37]. 19	
 In Takenouchi-Kosaki syndrome (TKS; MIM #616737), caused by mutations in the GA 20	
GTPase CDC42, which regulates bidirectional Golgi transport by regulating the cargo sorting 21	
and carrier formation functions of COPI [38], affected patients show a range of phenotypes 22	
affecting different organs, including ID and either POM or congenital microcephaly (reviewed 23	
in [39]). 24	
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 A neuromuscular syndrome with microcephaly noticeable from the 4th postnatal month 1	
has been described in an individual who also displayed developmental delays, seizures, 2	
hypotonia and muscular dystrophy [40]. Brain MRI revealed delayed myelination and a 3	
thinning of the corpus callosum. The molecular cause was a loss of function of the GOLGA2 4	
gene (MIM #602582), which encodes GM130, a multifunctional golgin involved in both the 5	
assembly/maintenance of GA structure and the regulation of the secretory pathway and vesicle 6	
tethering to the cis-Golgi compartment through interactions with RAB1B, P115 etc.; GM130 7	
also binds to other RAB proteins involved in membrane traffic regulation at the ER/Golgi 8	
interface, such as RAB2 and RAB33B [41-43]. 9	
 Autosomal recessive mental retardation 61 (MRT61; MIM #617773), also called 10	
Alwadei syndrome, is a POM syndrome that includes profound ID, epilepsy in two cases and a 11	
thin corpus callosum [44]; it has been found to be caused by mutations in IPORIN (MIM 12	
#617773), a protein encoded by the RUSC2 gene. Little is known about the RUSC2 protein 13	
except that it is ubiquitous and highly expressed in the brain, and interacts with both RAB1B 14	
and possibly directly with GM130 [45]. 15	
 Cohen syndrome (COH; #MIM 216550) is an autosomal recessive disorder 16	
characterized by motor delays, progressive retinal dystrophy and severe myopia, hypotonia, 17	
joint hypermobility and progressive POM associated with ID [46], associated at times with 18	
non-neurological signs [47]. Brain MRI reveals a relatively thicker but more compact corpus 19	
callosum in some patients, associated with markedly smaller sagittal diameters of the brain 20	
stem [48]. COH1, the only gene associated with Cohen syndrome so far, encodes the vacuolar 21	
protein-sorting protein VPS13B, a large peripheral membrane protein that is actively recruited 22	
at the GA by RAB6 [49,50]. VPS13B likely plays a specific role in the dynamics and function 23	
of the GA, in particular during neuronal maturation. 24	
Rasika et al, Golgipathies and Neurodevelopment 
	 10	
 Progressive Cerebello-Cerebral Atrophy type 2 or Ponto-Cerebellar Hypoplasia type 1	
2E (PCCA2/PCH2E; MIM #615851) is an autosomal recessive neurodegenerative disorder 2	
characterized by normal development during the initial months of life, followed by motor 3	
delays, progressive POM, progressive spasticity and epileptic seizures by two years of age [51]. 4	
Brain MRI reveals a gradual decrease in cerebral white matter associated with delayed 5	
myelination and thinning of the corpus callosum [51]. The responsible gene encodes VPS53, 6	
another vacuolar protein-sorting protein that participates in the transport and recycling of 7	
endosome-derived transport vesicles [52]. VPS53 is part of two large multisubunit complexes 8	
named Golgi-associated retrograde protein (GARP) and Endosome-associated recycling protein 9	
(EARP), that ensure the proper tethering between endosomes and their acceptor compartment 10	
[53,54]. Both complexes cooperate with SNAREs for subsequent membrane fusion. GARP has 11	
been found to interact with RAB6A at the TGN [55] and EARP associates with RAB4-12	
containing vesicles [54]. A previously unknown neurodevelopmental disorder linked to a 13	
mutation in yet another GARP/EARP subunit, VPS51, also appears to exist, based on our own 14	
observations (case report in preparation) as well as a BioRxive description of a 6-year-old 15	
patient with severe global developmental delay, pontocerebellar abnormalities, microcephaly, 16	
hypotonia, epilepsy and several systemic and peripheral dysfunctions (BioRxiv 409441, 2018).  17	
 A pontocerebellar hypoplasia caused by TBC1D23 mutations (PCH11; MIM #617695) 18	
has been shown in two different reports to be associated with POM or microcephaly of 19	
unknown onset, along with various other neurodevelopmental deficits and neurological signs 20	
(including a hypoplastic corpus callosum, as seen in several Golgipathic POMs, severe 21	
cognitive delays, motor weakness or lack of motricity, behavioral problems etc.) [56,57]. 22	
TBC1D23, like TBC1D20 in Warburg-Micro syndrome, appears to be a RAB GAP (although 23	
neither its GTPase activity nor its RAB specificity has been clearly evidenced so far). It is 24	
localized at the trans-Golgi and regulated by the small GTPases ARL1 and ARL8, and appears 25	
to mediate the binding of endosomal vesicles to golgin-245 and golgin-97 on trans-Golgi 26	
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membranes to mediate retrograde transport [58]. It has been implicated in the regulation of 1	
neuronal migration/positioning during corticogenesis, as well as neurite/axon differentiation 2	
[56]. 3	
 Autosomal recessive periventricular heterotopia with microcephaly (ARPHM; MIM 4	
#608097) has been described in several patients to be caused by ARFGEF2 mutations. The 5	
microcephaly in these reports is progressive postnatally in three reports [59-61] and of 6	
unknown onset/progression in one [62]. The patients also display severe developmental delays 7	
and ID, epilepsy, brain atrophy and myelination delays associated with a thin corpus callosum. 8	
ARFGEF2 encodes BIG2, a GA protein responsible for interior membrane trafficking in the 9	
trans-Golgi network and endosomes [63]. BIG2 interacts with RAB11, a trans-Golgi protein 10	
involved in diverse functions such as synaptic transmission, but also neuronal migration and 11	
axonal growth, functions that could explain the phenotypes seen in the reports above [64,65]. 12	
 MEDNIK syndrome (MEDNIK; MIM #609313) is caused by mutations in AP1S1, a 13	
subunit of one of the five adaptor protein complexes (AP1-5), located at the trans-Golgi and in 14	
endosomes, that match cargo molecules, including neurotransmitters (and in the case of AP1S1, 15	
specifically, the copper pumps ATP7A and B) to their carriers (reviewed in [66]). Symptoms of 16	
MEDNIK syndrome, although predominantly cutaneous, include POM in addition to other 17	
typical neurological signs such as moderate to severe ID and deafness [67]. Montpetit and 18	
colleagues also mention the occurrence of peripheral neuropathy and microcephaly in the 19	
original French-Canadian cohort, without indicating age of onset, when discussing their animal 20	
model	[68], although the original article by Saba and colleagues and subsequent discussions of 21	
this cohort only mention brain "atrophy" [67-69]. In addition, mutations in AP1S2 cause 22	
Pettigrew syndrome (PGS, MIM #304340), an X-linked disorder characterized by ID, seizures, 23	
Dandy-Walker malformation and microcephaly, possibly postnatal, although head 24	
circumference was variable in the original family	[70,71]. 25	
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 COG-associated Congenital Disorders of Glycosylation (CDGs) represent one subgroup 1	
of a very large family of multisystemic autosomal recessive pathologies involving dysfunctions 2	
in the processing of N- and O-linked glycans. While most of the mutations identified so far 3	
involve genes encoding glycosylation enzymes [72], the CDGs described in this paragraph are 4	
caused by defects in one of the 8 subunits of the Conserved Oligomeric Golgi (COG) complex, 5	
localized to the cis- and medial-Golgi as well as surrounding vesicles [73]. The COG complex 6	
is thought to act as a tethering factor, in particular during intra-GA and retrograde GA-to-ER 7	
trafficking, where it mediates the recycling of glycosyltransferases [74], suggesting that the 8	
incidence of CDG when COG subunits are mutated is likely due to the inability of these 9	
glycosylation enzymes to reach their target proteins [73]. COG-associated CDGs are associated 10	
with multiple neurological manifestations, including POM in patients carrying mutations in 11	
COG1 (MIM #611209), COG2 (MIM #617395), COG4 (MIM #613489), COG5 (MIM 12	
#613612), COG7 (MIM #608779) and COG8 (MIM #611182) [75-81]. Brain MRI has revealed 13	
hypoplasia of the corpus callosum in four patients [77,78] and brainstem atrophy in one case 14	
[75]. COG6 mutations have also been associated with borderline POM in Shaheen syndrome 15	
(SHNS; MIM #615328) as well as a CDG with congenital microcephaly (MIM #614576) 16	
[82,83]. Interestingly, the COG complex has been shown to interact with molecules at all levels 17	
of GA organization and trafficking as well as a number of GA-associated RABs (see [4] for an 18	
overview). 19	
 Another family of GA-associated proteins whose mutation gives rise to a wide range of 20	
CDGs with neurological phenotypes is the solute carrier family 35 (SLC35), whose members 21	
carry a variety of molecules, mostly sugars, to the GA for the glycosylation of proteins. 22	
Mutations in SLC35A3 have been associated with POM and ID [84] in a syndrome 23	
characterized by arthrogryposis, mental retardation and seizures (AMRS; MIM #615553). 24	
Similarly, mutations in SLC35C1 give rise to CDG2C (MIM #266265), in which severe ID and 25	
POM have also been noted [85], while mutations in other family members give rise to various 26	
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CDGs with ID, microcephaly of unknown onset, and other neurological manifestations (e.g. 1	
SLC35A1: CDG2F, MIM #603585; SLC35A2: CDG2M, MIM #300896).  2	
 Among CDGs caused by a defective trafficking mechanism, rather than an enzymatic or 3	
metabolic deficiency, and including POM, psychomotor delays and white matter abnormalities 4	
among their clinical signs, should be included CDG2K, caused by mutations in the 5	
transmembrane GA protein TMEM165 (MIM #614727). While the exact function of this 6	
protein is not yet known, it is probably an ion transporter that plays a role in pH, calcium or 7	
manganese homeostasis, and mutations also appear to affect GA morphology [86,87]. 8	
 9	
II. Other microcephalies or macrocephalies related to impaired GA function 10	
 A number of other reports of patients with microcephalies linked to mutations in GA-11	
associated proteins exist in the literature. However, data on whether these microcephalies are 12	
congenital or postnatal (or congenital but progressive after birth) is not always available. 13	
Further studies might well turn up other syndromes where a POM or a progressive worsening 14	
of microcephaly would indicate a defect in maturation (including trafficking or biosynthetic 15	
defects) or other processes that take place later in development, such as gliogenesis, as opposed 16	
to a congenital microcephaly that would indicate a deficit in the production of new neurons 17	
earlier in development, even though these different microcephalies are likely to lie along the 18	
same continuum rather than being mutually exclusive. The other side of the coin is that 19	
mutations in several GA-related proteins appear to result in macrocephaly, possibly indicating 20	
an opposite effect on the regulation of neurogenesis or neuronal apoptosis during maturation. A 21	
few examples of these other microcephalies and macrocephalies linked to GA protein 22	
mutations are given below (summarized in Table 2). 23	
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 Mutations in the WDR62 gene, which codes for a WD40 repeat protein highly expressed 1	
in the developing brain, cause autosomal recessive primary microcephaly 2 (MCPH2; MIM 2	
#604317) with seizures and ID in addition to congenital microcephaly [88,89]. Interestingly, 3	
even though it is best known for its presence at the centrosome during mitosis and appears to 4	
play a critical role in neuronal progenitor proliferation during corticogenesis, WDR62 also 5	
associates with GM130 and is localized at the GA during interphase, where its function is 6	
unknown [89]. Similarly, at least two other MCPH genes encode products that associate with 7	
the GA. Autosomal recessive primary microcephaly 3 (MCPH3; MIM #604804) is related to 8	
mutations in the CDK5 regulatory subunit-associated protein 2, CDK5RAP2 [90], which plays 9	
an important role in progenitor division during neurogenesis [91,92]. Interestingly, 10	
CKD5RAP2 is necessary for microtubule nucleation and organization not only at the 11	
centrosome but also at the GA [93,94]. Similarly, we and others have found that autosomal 12	
recessive primary microcephaly 17 (MCPH17; MIM #617090) is caused by mutations in the 13	
gene for the Citron Rho-interacting serine/threonine kinase, CIT [95,96]. The longer CIT-K 14	
protein, which localizes at the cleavage furrow and midbody during cell division (reviewed in 15	
[97]), is known from animal models to play a role in cytokinesis and progenitor survival during 16	
neurogenesis [98], while the shorter brain-specific isoform, CIT-N, is known to be enriched at 17	
the somatic GA of certain neurons as well as in dendrites where it interacts with peripheral 18	
Golgi outposts and plays a key role in the maintenance of dendritic spines [99,100].  19	
 Mutations in TRAPPC11, a subunit of the TRAPP complex that plays a role in ER-GA 20	
trafficking and activates several RABs, as described above, lead to a limb girdle muscular 21	
dystrophy (LGMDR18; MIM #615356) with microcephaly of unknown onset, myopathy, 22	
infantile hyperkinetic movements, ataxia, and ID [101,102].  23	
 A microcephalic dwarfism syndrome (SRMMD; MIM #617164) characterized by, in 24	
addition to microcephaly, facial dysmorphism, severe micrognathia, rhizomelic shortening and 25	
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mild developmental delay has been associated with heterozygous mutations in ARCN1 [103]. 1	
ARCN1 (COPD) encodes Archain 1, the delta subunit of the vesicular coat protein COPI, 2	
necessary for both intra-GA and GA-ER retrograde transport, and ARCN1 haploinsufficiency 3	
leads to COPI-mediated transport defects. In addition, a hypomorphic missense mutation in the 4	
COPB2 gene, encoding the beta subunit of COPI, has also recently been found to be the cause 5	
of a primary autosomal recessive microcephaly (MCPH19; MIM #617800) in which the 6	
congenital microcephaly is associated with severe developmental delay, cortical blindness and 7	
spasticity [104]. COPB2 appears to be involved not only in retrograde GA-ER transport, 8	
possibly interacting with DYMECLIN [7], but in early neuronal proliferation and apoptosis 9	
[104].  10	
 A PEHO (progressive encephalopathy with edema, hypsarrhythmia and optic atrophy) -11	
like syndrome (PEHOL; MIM #617507) caused by a mutation in the CCDC88A gene coding 12	
for GIRDIN, a coiled-coil GA protein, shows, in addition to profound psychomotor delay, 13	
seizures and progressive brain atrophy, severe congenital microcephaly in all patients, and 14	
dysmyelination in one case [105]. GIRDIN, also known as KIAA1212, appears to be involved 15	
in the migration and positioning of new neurons, controlling soma size and dendritic branching 16	
[106]. 17	
 AP4-deficiency syndrome is caused by a mutation in a subunit of another of the five 18	
adaptor protein complexes, AP1-5, mentioned above (reviewed in [66]). AP4-deficiency 19	
syndrome, which includes a very large range of phenotypes, may be included among the large 20	
number of hereditary spastic paraplegias	 [107]. Among them, AP4E1 mutations (MIM 21	
#613744) lead to a form of hereditary spastic paraplegia with congenital microcephaly, ID, thin 22	
corpus callosum, psychomotor deficits and spasticity [108-110], which Moreno-de-Luca and 23	
colleagues found to be similar to another hereditary spastic paraplegia caused by mutations in 24	
AP4M1 (MIM #612936), in which several patients displayed microcephaly in addition to other 25	
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neurological signs [111]. Similarly, Abou Jamra and colleagues also found microcephaly, along 1	
with a variety of other symptoms in patients with AP4B1 (MIM #614066) and AP4S1 mutations 2	
(MIM #614067) [108]. Surprisingly, microcephaly of unknown onset associated with ID has 3	
also been noted in Hermansky-Pudlak syndrome 2 (HPS2; MIM #608233), not commonly 4	
thought to be associated with neurodevelopment; in this disorder, mutations in AP3B1 5	
principally lead to oculocutaneous albinism, immunodeficiency and hematological 6	
abnormalities [112]. 7	
 As in the case of the TRAPP and AP protein families, mutations in another SLC family 8	
member, SLC9A6, are also associated with other forms of microcephaly (congenital, 9	
progressive, or of unknown onset) and severe ID in the X-linked mental retardation known as 10	
Christianson syndrome (MRXSCH; MIM #300243) [113-115]. 11	
 In an early infantile epileptic encephalopathy (EIEE49, MIM #617281) caused by 12	
mutations in DENND5A, a gene encoding a GA-localized GTPase activator thought to play a 13	
role in neuronal differentiation, almost all affected individuals show microcephaly in addition 14	
to various other neurological signs, including seizure onset in the neonatal period, global 15	
developmental delay with ID and lack of speech, hypotonia, spasticity etc. [116,117]. 16	
DENND5A acts as a GEF for the neuronal GA-specific GTPase RAB39 [118], which is 17	
involved in regulating the number and morphology of neurite growth cones and in synapse 18	
formation and maintenance, including alpha-synuclein homeostasis. However, deficits in 19	
RAB39B are also associated with an X-linked form of ID with macrocephaly rather than 20	
microcephaly (MRX72; MIM #300271)	[119,120]. Macrocephaly is also a feature of RAB39B-21	
associated early-onset Parkinsonism or Waisman syndrome (WSMN; MIM #311510) 22	
[121,122].  23	
 Mutations in another GTPase activator, HERC1, which is localized to the cytoplasm and 24	
GA/vesicular compartments and acts as a GEF for ARF1, and possibly RAB3A and RAB5 25	
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[123], also result in a macrocephaly syndrome with dysmorphic facies and psychomotor 1	
retardation (MDFPMR; MIM #617011) [124-126].  2	
 Similarly, in autosomal dominant mental retardation 48 (MRD48; MIM #617751) 3	
mutations in the gene encoding the small Rho GTPase RAC1, which appears to interact with 4	
various GA proteins and to play a distinct role in neuronal progenitor proliferation, lead to ID 5	
with either microcephaly or macrocephaly, as well as a developmental delay, seizures, absent 6	
speech and a number of defects on MRI [127]. Interestingly, SPATA13 (also known as ASEF2), 7	
encoding a GEF for both RAC1 and CDC42 (involved in Takenouchi-Kosaki syndrome, as 8	
mentioned above) that is enriched in the prenatal frontal cortex and plays a role in dendritic 9	
spine formation and cell migration, possibly by regulating actin cytoskeletal remodeling 10	
[128,129], is among a set of 26 newly identified ID genes [130]. 11	
 Another GA-associated gene implicated in corticogenesis is the gene for the 12	
pseudokinase STRADA (also known as STE20 related kinase adaptor alpha, or LYK5), 13	
deletions in which give rise to macrocephaly in a syndrome encompassing polyhydramnios, 14	
megalencephaly and symptomatic epilepsy (PMSE; MIM #611087) [131,132]. STRADA 15	
appears to form a complex with STK25 and the golgin GM130 to regulate GA morphology and 16	
positioning, thus controlling neuronal differentiation and integration during development [133]. 17	
 18	
III. GA protein mutations associated with other neurodevelopmental anomalies 19	
 Not all GA proteins appear to be associated with microcephalic or macrocephalic 20	
syndromes when mutated. However, a number of GA proteins do have other significantly 21	
neurodevelopmental effects involving either the central or peripheral nervous system, and lead 22	
to phenotypes that include ID, ataxias, peripheral neuropathies or sensorineural loss. Some of 23	
these are described below, and also summarized in Table 3 (excluding GA-localized enzymes 24	
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whose role lies primarily in protein or lipid biosynthesis/modification, and that are thus likely 1	
to have metabolic effects rather than mechanistic ones). 2	
 Many GA proteins other than those described in Sections I and II above are implicated 3	
in various forms of ID, even without being associated with microcephaly or macrocephaly. For 4	
example, mutations in the RAB-GDP dissociation inhibitor GDI1 are responsible for a non-5	
syndromic X-linked form of ID (MRX41/MRX48; MIM #300849) [134-136].  6	
A non-RAB molecular partner of BIG2 (ARFGEF2), which, as we have discussed 7	
above, causes a periventricular heterotopia and progressive microcephaly, is another GA 8	
protein, FILAMIN alpha (FLNA), that plays a role in neuronal migration by regulating the 9	
relocalization of BIG2 and the activation of ARF1 at the cell membrane [137]. Mutations in 10	
FLNA lead to X-linked periventricular nodular heterotopia (PVNH1; MIM #300049), 11	
characterized by brain structural abnormalities and ID, at least in males, but with no known 12	
microcephaly (reviewed in [138]). 13	
 Mutations in the gene for phosphofurin acidic cluster sorting protein, PACS1, a trans-14	
Golgi protein involved in the trafficking of FURIN, lead to Schuurs-Hoeijmakers syndrome, an 15	
autosomal dominant mental retardation (MRD17; MIM #615009), characterized by ID, 16	
dysmorphic features, and brain MRI defects in addition to skeletal defects [139].  17	
 Similarly, autosomal recessive mutations in SCYL1, which encodes a protein located at 18	
the interface between the GA and COPI-coated vesicles and likely involved in trafficking 19	
functions, lead to another form of autosomal recessive spinocerebellar ataxia (SCAR21; MIM 20	
#616719), characterized by cerebellar atrophy, peripheral neuropathy and mild ID [140].  21	
Several mutations in the BICD2 gene, which encodes the golgin BICAUDAL2 that 22	
interacts with the dynein-dynactin motor complex and RAB6A, have been shown to cause an 23	
autosomal dominant form of spinal muscular atrophy (SMALED2; MIM #615290) [141-143]. 24	
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Similarly, mutations in KIF1C, a kinesin family motor protein that interacts with RAB6 to 1	
mediate GA tethering [144], lead to an autosomal recessive form of hereditary spastic 2	
paraplegia, spastic ataxia 2 (SPAX2; MIM #611302) [145-147]. 3	
 Mutations in the TANGO2 gene, which encodes a protein thought to be involved in 4	
loading cargo into vesicles at the ER but is also localized at the GA, lead to a complex 5	
syndrome characterized by metabolic encephalomyopathic crises, recurrent, with 6	
rhabdomyolysis, cardiac arrhythmias, and neurodegeneration (MECRCN; MIM #616878), 7	
with multiple neurodevelopmental manifestations including seizures and ataxia [148,149]. 8	
 Mutations in GOSR2, a GA SNARE complex member, lead to early-onset ataxia and 9	
progressive myoclonic epilepsy (EPM6; MIM #614018) in childhood and skeletal deformities 10	
by adolescence [150,151]. 11	
 A cis-Golgi protein encoded by RETREG1 or FAM134B has been found to be mutated 12	
in hereditary sensory and autonomic neuropathy type IIB (HSAN2B; MIM #613115), 13	
characterized by childhood onset autonomic neuropathy, and heavily impaired sensory and 14	
sometimes motor function [152]. 15	
 Among the GA-associated genes involved in sensorineural loss, OSBPL2, which 16	
encodes a fatty-acid receptor, oxysterol binding protein-like protein 2, is mutated in a 17	
nonsyndromic autosomal dominant form of deafness with childhood onset (DFNA67; MIM 18	
#616340) [153,154]. In Hermansky-Pudlak syndrome 1 (HPS1, MIM #203300), a syndrome 19	
usually characterized in humans by albinism and excessive bleeding, as in HPS2 (discussed in 20	
Section II), mutations in the AP3D1 adaptor complex subunit give rise to a phenotype hearing 21	
loss in addition to neurodevelopmental delay and generalized seizures (HSP10; MIM #617050) 22	
[155]. Several of the genes and syndromes described above also have an impact on vision 23	
(several AP and COG subunits, RAB3GAP2, and TBC1D20, to name a few). 24	
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 Sometimes, mutations in GA genes that are not thought to be associated with 1	
neurological symptoms might in fact have unnoticed neurodevelopmental effects, as in the case 2	
of the Hermansky-Pudlak syndromes, as seen above. In other cases, disorders considered to be 3	
neurodegenerative might have a neurodevelopmental component in rare early onset forms, such 4	
as some spinocerebellar ataxias: type 2 (MIM #183090, ATXN2), type 5 and 14 (MIM 5	
#600224; MIM #615386, SPTBN2) and type 8 (MIM #610743, SYNE1) [156]. 6	
 The GA also plays an essential role in the biosynthesis or modification of the cargo 7	
being transported. While these are generally considered to be "metabolic" disorders and are 8	
related more to the modification of trafficked molecules than to trafficking per se, mutations in 9	
many of these also have neurodevelopmental consequences (for a brief overview, see [72]). For 10	
instance, it is the site of synthesis of some glycolipids and sphingomyelin, a major component 11	
of myelin and essential for normal morphogenesis or plasticity of membrane-rich cell types 12	
such as neurons (during migration, rapid axonal growth or dendritic arborization etc.) or 13	
oligodendrocytes (for the generation of the myelin sheath), from lipid precursors synthesized in 14	
the ER (glycerol phospholipids, cholesterol and ceramide). Mutations in genes involved in lipid 15	
biosynthesis and processing have also been associated with several neurodevelopmental 16	
defects. For example, a mutation in ACER3, encoding an ER and Golgi ceramidase involved in 17	
sphingolipid metabolism, has been identified in a family with progressive impairment and 18	
regression of neurodevelopment during the first year of life, leukodystrophy-like signs and 19	
peripheral neuropathy (PLDECO, MIM #617762) [157]. Another GA gene involved in lipid 20	
metabolism and that leads to neurodevelopmental deficits is that encoding DDHD domain 21	
containing 2 (DDHD2), a phospholipase with a major role in brain triglyceride metabolism 22	
[158], mutations in which result in hereditary spastic paraplegia type 54 (SPG54, MIM 23	
#615033) [159]. Mutations in the PGAP2 and PGAP3 genes (post-GPI attachment to proteins 2 24	
and 3), which are essential for the glycolipid remodeling of GPI anchor proteins, have been 25	
associated with developmental delays and ID, in addition to microcephaly in several families 26	
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(HPMRS3, MIM #614207 and HPMRS4, MIM #615716) [160-164], while PGAP1 has also 1	
been linked to ID [165,166]. 2	
 Among the cargo-modifying enzymes present in the GA are a very large complement of 3	
different glycosyltransferases and glycosidases, in addition to enzymes responsible for adding 4	
or removing phosphate, sulphate, lipid and other groups from proteins. To give a few examples, 5	
mutations in the acetylglucosaminyltransferase gene MGAT2, a member of the N-glycosylation 6	
pathway, lead to CDG type IIa (CDG2A, MIM #212066), characterized by seizures, 7	
developmental delays and ID in addition to other symptoms [167]. Another member of the N-8	
glycosylation pathway is β1,4 galactosyltransferase I, implicated in severe forms of CDG-IId 9	
(CDG2D, MIM #607091) with neurological deficits, hydrocephalus, myopathy and defective 10	
blood clotting [168]. CDG type II is also caused by mutations in the mannosidase gene 11	
MAN1B1, which lead to a syndrome characterized by ID and truncal obesity, while INPP5E 12	
(inositol polyphosphate-5-phosphatase E) mutations have been implicated in the 13	
neurodevelopmental disorders Joubert (JBTS1, MIM #213300) and MORM syndromes 14	
(MORMS, MIM #610156) [169,170], the latter of which also includes ID and truncal obesity. 15	
Several types of muscular dystrophy with neurological involvement are also caused by defects 16	
in GA glycosylation genes (e.g. FKRP, LARGE, POMGnT1). Similarly, a variety of members 17	
of the solute carrier families (SLC), which transport various metabolites (sugars, acetylCoA, 18	
zinc…) are involved in CDGs and other neurodevelopmental disorders including spastic 19	
paraplegias, ID, epilepsy etc [2].  20	
 Another GA protein family is that of the copper-transporting P-type ATPases, ATP7A 21	
and B (reviewed in [171]), which are specifically trafficked by AP1S1, whose mutation causes 22	
MEDNIK syndrome (mentioned in Section I above). Under basal conditions, ATP7A and B, 23	
which are ion pumps, are located in the trans-Golgi network (TGN) and translocates copper 24	
across intracellular membranes into the secretory pathway for incorporation into copper-25	
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dependent enzymes. Their mutation, while having multisystemic consequences due to copper 1	
deposition in the liver and skin, for example, in addition to the brain, has been linked to 2	
Menkes disease (MNK, MIM #309400) or occipital horn syndrome (OHS, MIM #304150), or 3	
spinal muscular atrophy (SMAX3, MIM #300489) (ATP7A), all disorders with a childhood 4	
onset, or dystonia and neurodegeneration of either childhood or late onset (ATP7B). 5	
 6	
The link between Golgipathies, GA function and neurodevelopment 7	
 What is the explanation for the exceptionally large spectrum of diseases and symptoms 8	
associated with defective GA proteins above, even when one limits the discussion to those with 9	
neurodevelopmental consequences?  10	
 The GA is not only involved in but lies at the crossroads of a number of distinct and 11	
crucial cellular processes, some of which have only recently begun to be elucidated. In 12	
addition, individual GA proteins themselves often participate in more than one function or 13	
pathway, depending on the cellular context, developmental stage and the pathophysiological 14	
state, and some proteins, such as the small RAB GTPases, belong to extended families with a 15	
whole gamut of functions, both within and outside the GA. However, much is still unknown 16	
regarding the precise functions and the molecular partners of the great majority of GA proteins, 17	
and existing information often comes from lower species or organs outside the nervous system. 18	
Despite these overlaps and restrictions, obtaining even an incomplete understanding of some of 19	
these functions and proteins may provide insights into the complex repercussions of their 20	
mutation or deregulation, including the various neurodevelopmental processes impacted. 21	
Figure 1 illustrates the relationship between some of the principal GA functions and the 22	
different stages of neurodevelopment in which they are implicated, taking the central nervous 23	
system as an example. Understanding these functions and how they evolve over the lifespan of 24	
the cell and the organism would also help elucidate the reason why mutations in some families 25	
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of GA proteins appear to cause a spectrum of deficits rather than discrete phenotypic entities 1	
(e.g. both congenital microcephalies and POM in the case of defective TRAPP, AP or SLC 2	
complex subunits).  3	
 Maintenance of GA structure, integrity and position: 4	
 A distinctive characteristic of the GA in the cells of mammals and other vertebrates is 5	
its structure – it is made up of stacks of flattened cisternae, as in protists, plants and 6	
invertebrates, but these stacks are linked to each other to form a "ribbon" [172,173]. Cisternal 7	
stacking is necessary for normal trafficking, while the ribbon structure is thought to play a role 8	
in higher order functions such as mitosis and apoptosis, cell polarity/migration and stress 9	
responses (reviewed in [174,175]). A number of GA proteins are involved in regulating this 10	
typical structure and the integrity of the GA. Prominent among these are various members of 11	
the coiled-coil golgin family of proteins (e.g. GM130, GIANTIN, P115, GOLGIN-45, 12	
GMAP210, GIRDIN etc.), many of which interact with coiled-coil GRASP proteins and small 13	
GTPases or GTP-binding proteins of the RAB, ARF and ARL families to control cisternal 14	
structure and stacking in the GA. (reviewed in [174-176]). Many of the GA-associated 15	
GTPases are in turn regulated by families of regulatory proteins, such as the GEFs and GAPs, 16	
which act at various points and target effector molecules in the trafficking pathway. Among the 17	
GA-associated members of these large families of proteins, some are specifically expressed in 18	
neural tissue, for example RAB6B [177] and to some extent RAB6C [178]. Several golgins 19	
(e.g. Bicaudal D and GMAP210) and RAB GTPases (for instance, the multifunctional RAB6) 20	
are involved in interactions between the GA and the microtubule cytoskeleton, including 21	
molecular motors such as DYNEIN, and help in the organization of the GA ribbon by 22	
recruiting GA stacks to the microtubule organizing center (MTOC). Some, such as GM130, 23	
through their interactions with other polarity-determining kinases as well as their role in 24	
microtubule nucleation and organization [179-182], dictate the polarity of the GA and thus of 25	
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the cell or neuron as a whole [183], thus controlling its correct differentiation and function. The 1	
fragmentation of the GA ribbon through the phosphorylation of the GRASPs and other 2	
molecules might also allow GA repositioning and thus migration, growth or differentiation 3	
[184] (fragmentation is also essential for the progression of the cell cycle, discussed below). In 4	
addition to structural changes, GM130 and GRASP65 also form part of signaling cascades that 5	
regulate cell migration [181].  6	
 Secretory and membrane trafficking: 7	
 GA structure and integrity and many of the large array of molecules that control them 8	
are also essential for the various steps involved in vesicular transport – coat components and 9	
adaptors that control vesicle targeting and recognition, the coiled-coil golgins necessary for 10	
their capture and the SNAREs and COGs that help in tethering and fusion, RAB and other 11	
small GTPases that mediate the choreographed attachment and detachment of molecules at 12	
each step, adaptors, activators and inhibitors for each of the above etc. Interfering with these 13	
proteins or their interactions results in disrupted GA structure/organization and abnormal 14	
protein and lipid transport (see for example the effects of disrupting various RABs on GA 15	
structure, reviewed in [185]), important for both neuronal and oligodendrocyte function, 16	
including the rapid membrane expansion needed for the establishment of neuronal outgrowth 17	
and connectivity and myelination. Mutations in these genes are involved in a number of 18	
Golgipathies with diverse symptoms, including the large majority of the POM syndromes with 19	
white matter defects that we have listed above (Dyggve-Melchior-Clausen syndrome, Warburg-20	
Micro and Martsolf Syndromes, Cohen Syndrome Progressive Cerebello-Cerebral Atrophy 21	
Type 2 and other Pontocerebellar Hypoplasias, microcephalies related to mutations in the 22	
TRAPP complex and COG-related CDGs, to name a few) as well as a range of spinal muscular 23	
atrophies and paraplegias. Other functional consequences could be the disruption of neuronal 24	
migration to the appropriate target layers or regions, as a consequence both of membrane 25	
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trafficking deficits and the disruption of the MTOC function of the GA and thus of cellular 1	
polarity [4]. Certain syndromes characterized by epilepsy or seizures could thus be a result of 2	
either the aberrant connectivity caused by such migration defects, or the defective transport of 3	
neurotransmitters or their receptors/inhibitors to the synapse. Additionally, the occurrence of 4	
central hypogonadism, dwarfism, obesity etc. of unknown etiology in certain POM 5	
Golgipathies could conceivably be due to deficits in neuroendocrine secretory activity 6	
controlling bodily hormonal homeostasis. 7	
 Cell cycle regulation: 8	
 Closely related to the structure and position of the GA is its role in the cell cycle. The 9	
typical ribbon structure of the GA in mammalian cells is usually localized close to the 10	
centrosome, a position regulated among others by a number of GA-associated proteins, 11	
including those involved in its structure and trafficking function (see for review [186]). During 12	
mitosis, the GA loses its pericentriolar position, as it does its ability to function as an 13	
independent MTOC, and undergoes fragmentation to yield small tubular-reticular structures 14	
and dispersed vesicles. While GA fragmentation could be considered a logical prerequisite for 15	
the partitioning of the GA into the daughter cells, it appears that GA fragmentation is in fact a 16	
prerequisite for mitosis itself, and blocking GA fragmentation, for example by blocking 17	
GRASP phosphorylation, acts as a "Golgi checkpoint" for the progression of mitosis [187-189]. 18	
Failure of the GA to fragment results in the failure of Aurora-A recruitment at the centrosome, 19	
essential for mitosis	[190]. Several other GA proteins (for example GM130 and golgin-84) as 20	
well as non-GA proteins are also activated during fragmentation. In addition, a number of RAB 21	
GTPases including several GA-associated RABs, as well as the small G-protein ARF1 along 22	
with its activators and effectors, play essential roles at various steps of mitosis. Surprisingly, 23	
several GA proteins acquire new locations and functions during mitosis (reviewed in [188]). 24	
Some GA proteins, such as GM130, whose role in this regard has been described above, may 25	
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also play very specific roles in neurogenesis and neural progenitor division, by influencing cell 1	
polarity (reviewed in [191]) or the symmetry of mitosis, which plays a crucial role in the 2	
generation of different types of neuronal progenitors while still maintaining the pool of stem 3	
cells. For example, the asymmetric division of neural progenitor cells requires the interaction of 4	
the golgin GCP60 (also known as ACBD3 or PAP7) and Numb [192]. While the 5	
pathophysiological mechanisms underlying the syndromes characterized by macrocephaly 6	
mentioned above are not clear, most of the mutations detected result in a loss of function, and it 7	
is conceivable that uncontrolled proliferation or the dysregulation of the timing of symmetric 8	
versus asymmetric divisions during neurogenesis, could lead to the overproduction of certain 9	
neurons. In another instance of the overlap between the trafficking function of the GA and its 10	
role in neurogenesis, the trans-Golgi BIG2 protein encoded by ARFGEF2, essential for protein 11	
trafficking, is also involved in normal neural progenitor cell proliferation, migration and axonal 12	
growth in the developing mammalian cortex through its interaction with RAB11, another trans-13	
Golgi protein. The early microcephaly and aberrant corticogenesis noted in ARPHN, caused by 14	
ARFGEF2 mutations [59-62], could for example be due to defective neurogenesis and 15	
migration rather than defects in neuronal maturation or myelination. 16	
 It should not be forgotten that mutations in GA proteins whose function is essential 17	
early in neurodevelopment, for example during neurogenesis, might simply be embryonic lethal 18	
and thus pass unremarked. 19	
 Autophagy and apoptosis: 20	
 At the other end of the spectrum from cell proliferation and membrane expansion, the 21	
GA is also involved in normal or pathological cell death or the destruction of cellular contents. 22	
Both apoptosis and autophagy are normally occurring processes by which unwanted cells or 23	
cellular components are eliminated while limiting tissue damage (i.e. leakage of cellular 24	
contents). They occur during neurodevelopment, when the large excess of new neurons or 25	
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membranes produced is culled during the maturation of the CNS. In addition, they are also 1	
brought into play for the removal of damaged cells during conditions of stress or disease. In 2	
fact, the GA is increasingly thought to play a role in sensing stress and reestablishing cellular 3	
homeostasis; prolonged "Golgi stress", like ER stress, while not due to an intrinsic GA defect, 4	
nevertheless leads to impaired or abnormal GA function, contributing to pathogenesis and cell 5	
death, including by novel mechanisms other than apoptosis	[193]. 6	
 In autophagy, or more specifically, macroautophagy, cellular contents to be degraded 7	
are enveloped in a "phagophore" or "isolation membrane" and delivered to acidic lysosomes for 8	
destruction. There is evidence that the phagophore might bud directly from GA membranes, or 9	
alternatively, from the ER or ER-Golgi Intermediate Compartment [194,195]. The GA might 10	
additionally be directly involved in the degradation of undesirable cellular contents [196]. 11	
Several GA-associated RAB GTPases and their partners, normally involved in various stages of 12	
trafficking, also play key roles in the formation of the autophagosome	 [197-201], as do 13	
SNAREs, which are involved in autophagosome fusion (reviewed in [202]). Among other GA 14	
proteins, BECLIN1, a trans-Golgi protein involved in endosome-to-GA recycling, also plays a 15	
crucial early role in autophagosome formation (reviewed in [203]), by interacting with 16	
UVRAG, which normally mediates GA-to-ER retrograde transport by tethering COPI-coated 17	
vesicles but is displaced during autophagy [204]. Similarly, the trans-Golgi membrane-bound 18	
protein ATG9 is found in vesicles that contribute to autophagosome formation [199], and the 19	
regulation of its trafficking plays a crucial role in the induction of autophagy pathways 20	
[205,206]. Several coat adaptor proteins of the AP1, 2 and 4 classes are known to interact with 21	
ATG9, and are also necessary for autophagosome formation [207,208].  22	
 Apoptosis, resulting from mitochondrial membrane permeabilization in response to 23	
internal or external signals and leading cell death by strictly regulated molecular and cellular 24	
mechanisms, is mediated by members of the caspase and BCL-2 families of proteins. Much of 25	
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the evidence for the involvement of GA proteins in apoptosis comes from neurodegenerative 1	
disorders such as Alzheimer, Parkinson and Huntington Diseases, where the GA undergoes 2	
stress due to an accumulation of aberrant and misfolded proteins or peptides, also causing it to 3	
fragment (reviewed in [209-211]). However, some of the early machinery for apoptosis localize 4	
to the GA, and is involved in cleaving various GA proteins that also play a role in 5	
neurodevelopment (for example GRASP65, GM130 or GIANTIN). Their cleavage triggers the 6	
mitosis-like disassembly of the GA and subsequent apoptosis (reviewed in [212]). Some GA 7	
proteins also have a larger signal transduction role – GMAP210 and golgin-160 as well as 8	
cleaved p115 fragments are translocated to the nucleus during apoptosis, triggering further 9	
apoptotic changes [213,214]. It is certainly possible that mutations that interfere with the 10	
cleavage of such GA proteins or that lead to the production of truncated proteins would either 11	
curtail or augment apoptosis, with consequences for neurodevelopment ranging from 12	
insufficient neurogenesis to excess neurons that are not culled and that lead to macrocephaly, 13	
aberrant connectivity and related disorders.  14	
 Biosynthesis and processing of lipids and proteins: 15	
 As mentioned previously, the GA is also intimately involved in the post-translational 16	
modification of proteins and the biosynthesis of some lipids. In terms of the physiological 17	
effects of mutations in these proteins versus mutations in proteins involved in trafficking per se, 18	
there might be a convergence, since the functional consequences of the lack of delivery of a 19	
modified protein to its target intracellular compartment and the lack of its modification in the 20	
first place are likely to be similar in at least some respects. In addition, the highly specialized 21	
nature of the nervous system implies a corresponding adaptation of GA trafficking function in 22	
the component cells (for example, the occurrence of Golgi outposts in dendrites), and 23	
correspondingly, defects in GA enzyme function often lead to neurological consequences (also 24	
reviewed in [2,4]). A prime example of this convergence is provided by the CDGs, which could 25	
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be related to structural/mechanical deficits (e.g. due to the mutation of COG subunits necessary 1	
for vesicle tethering) or due to enzymatic deficits (due to the failure of glycosylation).  2	
 3	
Conclusion 4	
While the large number of neurodevelopmental Golgipathies described in this review 5	
contain some surprises, it appears as if the majority were, and are, simply hiding in plain sight. 6	
The GA is involved in a very large range of functions spanning every stage of a cell's lifespan; 7	
an even larger number of overlapping GA-associated proteins and pathways carry out or 8	
regulate these functions. It is therefore to be expected that as our knowledge of these proteins 9	
and pathways grows, and as modern sequencing methods provide a molecular diagnosis for 10	
more obscure syndromes, the range of phenotypes that we know to be caused by defective GA 11	
proteins and their partners will expand. This is especially true when one considers the essential 12	
roles played by the GA in the formation, growth and maturation of the brain and nervous 13	
system. In fact, the spectrum of syndromes in which mutations in GA-associated proteins are 14	
implicated, and the overlap in the cellular roles played by these proteins, evoke the intriguing 15	
idea that the GA might modify its role in keeping with the needs of the cell or the organism 16	
during its lifespan. For instance, the same proteins that are actively involved in cell cycle 17	
initiation or regulation during neurogenesis, when abundant proliferation is required, might be 18	
repurposed to lend a hand in neuronal migration, apoptosis or maturation, meet secretory 19	
trafficking needs during synaptogenesis and myelination as well as normal cellular function for 20	
the major part of the lifespan of the cell, and finally play a role in repair and damage control 21	
during aging (see also [215]). From this perspective, this vast array of neurodevelopmental 22	
Golgipathies appears not as isolated syndromes that differ from each other, but as points that 23	
fall along a few key functional continua, with flexible phenotypes that primarily reflect the 24	
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developmental stage at which function is interrupted or altered. Such an organelle-centric 1	
approach might eventually make it easier to understand the pathophysiology of these disorders. 2	
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TABLE	1.	Golgipathies	associated	with	Postnatal-Onset	Microcephaly	 
Disease/Syndrome	
 
#	MIM Mode	of	
Inheritance	
GA	protein Major	neurological	signs 
Dyggve-Melchior-Clausen	syndrome	
(DMC)	
 
223800	 AR	 DYMECLIN	 POM,	ID,	thin	corpus	callosum	
Warburg-Micro	syndrome		
(WARBM1-4)	
600118	
614225	
614222	
615663	
AR	
AR	
AR	
AR	
RAB3GAP1	
RAB3GAP2	
RAB18	
TBC1D20	
POM,	ID,	progressive	limb	
spasticity,	peripheral	axonal	
neuropathy,	visual	impairment,	
thin	corpus	callosum	
Neurodevelopmental	Disorder	with	
Microcephaly,	Epilepsy,	Brain	
Atrophy	
(NEDMEBA)	
617862	 AR	 TRAPPC6B	 POM,	ID,	hypotonia,	hand	tremors,	
seizures	
Autosomal	Recessive	Mental	
Retardation	13		
(MRT13)	
613192	 AR	 TRAPPC9	 POM,	ID,	thin	corpus	callosum	
Progressive	Childhood	
Encephalopathy	(PEBAS)	
617669	 AR	 TRAPPC12	 POM	or	PM,	truncal	hypotonia	
with	appendicular	spasticity,	visual	
impairment,	partial	agenesis	of	the	
corpus	callosum	
Autosomal	Recessive	Mental	
Retardation	61		
(MRT61)	
617773	 AR	 IPORIN	 POM,	ID,	thin	corpus	callosum	
Autosomal	Dominant	Mental	
Retardation	34		
(MRD34)	
616351	 AD	 COL4A3BP	 POM,	ID,	visual	impairment,	
seizures	
Cohen	syndrome		
(COH)	
216550	 AR	 VPS13B	 POM,	ID,	visual	impairment,	short	
and	thick	corpus	callosum	
Pontocerebellar	Hypoplasia	Type	2E	
(PCH2E)	
615851	 AR	 VPS53	 POM,	pontocerebellar	hypoplasia,	
progressive	spasticity,	seizures,	
thin	corpus	callosum	
Pontocerebellar	Hypoplasia	Type	11	
(PCH11)	
617695	 AR	 TBC1D23	 POM,	ID,	pontocerebellar	
hypoplasia,	thin	corpus	callosum	
Autosomal	Recessive	Periventricular	
Heterotopia	with	Microcephaly	
(ARPHM)	
608097	 AR	 BIG2	 POM,	ID,	periventricular	
heterotopia,	seizures,	thin	corpus	
callosum	
POM-associated	Congenital	
Disorders	of	Glycosylation	
(CDG	types	2C,	2E,	2F,	2G,	2H,	2I,	2J,	
2K,	2M,	2Q,	SHNS,	AMRS)	
611209	
617395	
613489	
613612	
615328	
608779	
611182	
603585	
300896	
615553	
266265	
614727	
AR	
AR	
AR	
AR	
AR	
AR	
AR	
AR	
XLD	
AR	
AR	
AR	
COG1	
COG2	
COG4	
COG5	
COG6	
COG7	
COG8	
SLC35A1	
SLC35A2	
SLC35A3	
SLC35C1	
TMEM165	
POM,	ID,	multiple	and	variable	
neurological	manifestations	
Mental	Retardation,	Enteropathy,	
Deafness,	Peripheral	Neuropathy,	
Ichthyosis,	Keratoderma		
(MEDNIK)	
609313	 AR	 AP1S1	 POM,	ID,	peripheral	neuropathy	
Takenouchi-Kosaki	syndrome		
(TKS)	
616737	 AD	 CDC42	 POM	or	PM,	ID,	seizures,	visual	
impairments,	thin	corpus	callosum	
Neuromuscular	syndrome	with	
Microcephaly	
602580*	 AR	 GM130	 POM,	central	hypotonia,	thin	
corpus	callosum	
Novel	Pontocerebellar	Hypoplasia	 NA	 AR	 VPS51	 POM,	ID,	pontocerebellar	
hypoplasia,	visual	impairment,	thin	
corpus	callosum		
 
AR=Autosomal	Recessive,	AD=Autosomal	Dominant,	XLD=X-linked	Dominant	
*OMIM	reference	corresponds	to	the	gene	instead	of	the	disease.   
 
 
TABLE	2.		
Golgipathies	associated	with	Primary	or	Unknown-onset	Microcephaly	or	Macrocephaly 
Disease/Syndrome	
 
#	MIM Mode	of	
Inheritance	
GA	protein Major	neurological	signs 
Autosomal	Recessive	Primary	
Microcephaly	type	2	
(MCPH2)	
604317	 AR	 WDR62	 PM,	ID,	seizures	
Autosomal	Recessive	Primary	
Microcephaly	type	3	
(MCPH3)	
604804	 AR	 CDK5RAP2	 PM,	ID	
Limb	Girdle	Muscular	Dystrophy	
(LGMDR18)	
615356	 AR	 TRAPPC11	 Microcephaly	of	unknown	onset,	
ID,	limb	spasticity,	seizures,	ataxia,	
visual	impairments	
Autosomal	Dominant	Microcephalic	
dwarfism	with	micrognathia	
(SRMMD) 
617164	 AD	 COPD	 PM,	ID,	mild	cerebellar	atrophy,	
visual	impairments,	thin	corpus	
callosum	
Autosomal	Recessive	Primary	
Microcephaly	type	19	
(MCPH19) 
617800	 AR	 COPB2	 PM,	ID,	spasticity,	visual	
impairments,	thin	corpus	callosum	
Progressive	Encephalopathy	with	
Edema,	Hypsarrythmia	and	Optic	
Atrophy-like	syndrome	
(PEHOL)	
617507	 AR	 GIRDIN	 PM,	ID,	severe	encephalopathy,	
seizures,	hypotonia,	peripheral	
hypertonia	with	spasticity,	visual	
impairments,	thin	corpus	callosum	
AP4-deficiency	Syndrome	 613744	
612936	
614066	
614067	
AR	
AR	
AR	
AR	
AP4E1	
AP4M1	
AP4B1	
AP4S1	
PM,	ID	
Spastic	paraplegia	
Neonatal	hypotonia	
Hermansky-Pudlak	syndrome	
(HPS2)	
608233	 AR	 AP3B1	 Microcephaly	of	unknown	onset,	ID	
Christianson	Syndrome	
(MRXSCH)	
300243	 XLD	 SLC9A6	 PM	or	Microcephaly	of	unknown	
onset,	ID,	seizures,	visual	
impairments	
Pettigrew	syndrome	
(PGS)	
304340	 XLR	 AP1S2	 Microcephaly	of	unknown	onset,	
ID,	seizures,	Dandy-Walker	
malformation	
Early	Infantile	Epileptic	
Encephalopathy	
(EIEE49)	
617281	 AR	 DENND5A	 Microcephaly	of	unknown	onset,	
ID,	spastic	tetraplegia,	seizures,	
visual	impairment,	corpus	callosum	
dysgenesis	
X-linked	form	of	ID	
(MRX72)	
Waisman	syndrome	
(WSMN)	
300271	
	
311510	
XLR	
	
XLR	
RAB39B	
	
RAB39B	
Macrocephaly	
ID	
Early	onset	Parkinsonism	
Macrocephaly,	Dysmorphic	Facies	
and	Psychomotor	Retardation	
(MDFPMR)	
617011	 AR	 HERC1	 Macrocephaly,	ID,	seizures,	
hypotonia,	ataxia	
Polyhydramnios,	Megalencephaly	
and	Symptomatic	Epilepsy	
(PMSE)	
611087	 AR	 STRADA	 Macrocephaly,	ID,	seizures,	
hypotonia	
Autosomal	Dominant	Mental	
Retardation	
(MRD48)	
617751	 AD	 RAC1	 Microcephaly	of	unknown	onset	or	
macrocephaly,	ID,	seizures,	thin	
corpus	callosum	
 
AR=Autosomal	Recessive,	AD=Autosomal	Dominant,	XLD=X-linked	Dominant,	XLR=X-linked	Recessive	 	
TABLE	3.	Neurodevelopmental	Golgipathies	without	Microcephaly 
Disease/Syndrome	
 
#	MIM Mode	of	
Inheritance	
GA	protein Major	neurological	signs 
Non-syndromic	form	of	ID	
(MRX41) 
300849	 XLD	 GDI1	 ID	of	variable	severity	
Periventricular	Nodular	Heterotopia	
(PVNH1)	
300049	 XLD	 FLNA	 ID	in	males	
Epilepsy	
Schuurs-Hoeijmakers	syndrome	
(SHMS)	
615009	 AD	 PACS1	 ID	with	remarkable	similarity	in	
facial	features	
Autosomal	Rcessive	Spinocerebellar	
Ataxia	
(SCAR21)	
616719	 AR	 SCYL1	 ID,	Cerebellar	atrophy;	peripheral	
neuropathy	
Autosomal	Dominant	Spinal	
Muscular	Atrophy	
(SMALED2) 
615290	 AD	 BICAUDAL	 Spasticity	
	
Autosomal	Recessive	spastic	Ataxia	
(SPAX2) 
611302	 AR	 KIF1C	 Cerebellar	ataxia	
Atrophy	of	the	corpus	callosum	
Metabolic	Encephalomyopathic	
Crises,	Recurrent	with	
Rhabdomyolysis,	Cardiac	
Arrythmias	and	Neurodegeneration		
(MECRCN)	
616878	 AR	 TANGO2	 Muscle	weakness,	ataxia,	seizures	
Progressive	Myoclonic	Epilepsy	
(EPM6)	
614018	 AR	 GOSR2	 Progressive	ataxia	
Seizures	
Neuropathy	Hereditary	Sensory	and	
Autonomic	type	IIB	
(HSAN2B)	
613115	 AR	 FAM134B	 Childhood	onset	autonomic	
neuropathy,	sensory	deficits,	loss	of	
myelinating	fibers	
Deafness	Autosomal	Dominant	67	
(DFNA67) 
616340	 AD	 OSBPL2	 Sensorineural	hearing	loss	
Hermansky-Pudlak	syndrome	
(HSP10)	
617050	 AR	 AP3D1	 Epilepsy	
Neurodevelopmental	delay	
Intractable	myoclonic	seizures	
 
AR=Autosomal	Recessive,	AD=Autosomal	Dominant,	XLD=X-linked	Dominant	
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Legend to Figure 1: Temporal relationship between major stages of central nervous 1	
system development and various physiological functions of the Golgi apparatus 2	
Schematic representation summarizing some of the physiological functions of the Golgi 3	
apparatus (GA) proteins (upper section) and major developmental processes of the central 4	
nervous system in which these proteins are involved during embryonic/fetal and postnatal life 5	
(lower section). Proteins involved in the maintenance of GA structure, integrity and position 6	
are required throughout life, as are those involved in the biosynthesis and modification of 7	
certain lipids and most proteins. However, the need for other GA functions increases 8	
periodically, and proteins involved in these functions may not play a role throughout life or 9	
may switch to other roles depending on the stage of the lifespan. For example, during 10	
neurogenesis and gliogenesis, when mitotic activity predominates, GA proteins involved in cell 11	
cycle regulation (yellow) would be expected to play a major role, and defects in these proteins 12	
would have maximum impact and lead to disorders reflecting a lack of neurons and glia. At 13	
later stages, other functions predominate, such as cellular polarity and microtubule organization 14	
(orange; particularly important for migration and morphogenesis, including the establishment 15	
and maturation of the axon and dendritic arbor), apoptosis (violet; crucial for the programmed 16	
death of the large excess of neurons produced), autophagy (pink; necessary to remodel the cell 17	
but also important in maintenance and repair throughout the lifespan, when it is involved in 18	
neurodegenerative processes) and secretory and membrane trafficking (blue; essential for the 19	
huge expansion of the cell membrane and secretory activity during synaptogenesis in neurons, 20	
branching of astrocytes and myelination by oligodendrocytes, but also necessary for neuronal 21	
and glial function throughout the lifespan). NB: the timeline of some of the processes 22	
described, for example neurogenesis and myelination, is still subject to debate; some processes 23	
involve two or more GA functions simultaneously. 24	
 25	

